Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Martha P. Mims, MD, PhD
Baylor College of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Baylor College of Medicine- Mcnair Campus
Houston, Texas, United States
- Ben Taub General Hospital
Houston, Texas, United States
- Chi St. Luke'S Health Baylor College of Medicine Medical Center
Houston, Texas, United States
- Harris Health System- Smith Clinic
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Dec 2020
- Primary completion
- 15 Nov 2028
- Completion
- 15 Nov 2028
- Last update posted
- 4 May 2026
- Registered enrollment
- 17
- Registry id
- NCT04626024
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.